MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
23.04
+2.03
+9.66%
After Hours: 23.14 +0.1 +0.43% 19:44 02/06 EST
OPEN
21.60
PREV CLOSE
21.01
HIGH
23.46
LOW
21.24
VOLUME
748.48K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.41B
P/E (TTM)
-5.5937
1D
5D
1M
3M
1Y
5Y
1D
Kodiak Sciences präsentiert erfolgreiche Phase-1b-Studienergebnisse für KSI-101 bei Makulaödem durch Entzündung
Reuters · 4d ago
Kodiak Sciences Reports Positive Phase 1b Results for KSI-101 in Macular Edema Secondary to Inflammation
Reuters · 4d ago
Kodiak Sciences: A Stellar Move
Seeking Alpha · 5d ago
Kodiak Sciences: GLOW2 Readout as Key Catalyst for Tarcocimab Upside and Broader Pipeline Optionality
TipRanks · 6d ago
Weekly Report: what happened at KOD last week (0126-0130)?
Weekly Report · 6d ago
Weekly Report: what happened at KOD last week (0119-0123)?
Weekly Report · 01/26 10:07
Kodiak Sciences Reaches Analyst Target Price
NASDAQ · 01/23 11:52
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 01/22 12:13
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.